Recognizing the strong link between obesity, T2DM, and HFpEF, the 2025 American Diabetes Association (ADA) Standards of Care granted a Level A recommendation for GLP-1 RAs with demonstrated benefit, specifically semaglutide, for reducing HF symptoms and physical limitations in patients with T2DM and obesity.(11) More recently, the SUMMIT trial showed that tirzepatide significantly reduced the composite risk of major HF events, including hospitalization and cardiovascular (CV) death, suggesting that dual GIP/GLP-1 agonism may further optimize outcomes.(14) However, the 2025 ADA Standards of Care reference only semaglutide as the GLP-1 RA with demonstrated benefit based on the evidence from the STEP-HFpEF trial program

Summary of Section 10 (Mini-List) Preoperative medical therapy reduces liver size and improves operative safety GLP-1 and dual agonist medications stabilize blood sugar and metabolic function Behavioral foundations developed before surgery improve postoperative success Medical therapy can fulfill insurance prerequisites meaningfully Patients with complex medical profiles benefit from structured preoperative support What Most Patients Can Expect From Treatment Over the First Weeks and Months Early Physiologic Changes During the First Four to Twelve Weeks During the early phase of medical weight loss treatment, most patients begin noticing subtle but meaningful changes in their appetite and relationship with food
The best GLP-1 breakfast is high in protein (25-30g), moderate in healthy fats, and includes fiber-rich carbs
doi: 10.1186/s13578-025-01378-x, 50 HuD.WeinerH
A Karger review found 18 reported cases of biotin use for hair and nail problems, all showing improvement though all patients had an identified underlying condition